STOCK TITAN

Telomir Pharmaceuticals (TELO) SEC Filings, Oct-Dec 2025

TELO NASDAQ

The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.

For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.

Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.

On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.

Rhea-AI Summary

Telomir Pharmaceuticals, Inc. reported favorable results from a full package of Good Laboratory Practice toxicology and safety pharmacology studies for its lead candidate, Telomir-1 (Zn-Telomir). The completed cardiovascular, respiratory, phototoxicity, and repeat-dose studies in in vitro systems and in rat and dog models showed Telomir-1 was generally well tolerated, with no treatment-related adverse or dose-limiting toxicities and only limited, reversible, non-adverse findings. In non-rodent dog studies, no test-article-related changes in blood pressure, heart rate, ECG parameters, or body temperature were seen after oral dosing, and oral studies showed consistent systemic exposure.

These results support advancement into first-in-human clinical trials, with no findings identified that would prevent clinical entry, subject to regulatory pathways. The company plans to submit an Investigational New Drug application in the first quarter of 2026 and aims to start first-in-human clinical studies in the first half of 2026 while continuing preclinical work in oncology and age-related diseases and preparing manuscripts and scientific conference submissions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
current report
-
Rhea-AI Summary

Telomir Pharmaceuticals, Inc. (TELO) announced new preclinical data on its investigational candidate Telomir-1 in prostate cancer models. In an in vitro study using androgen-responsive human prostate cancer LNCaP cells, Telomir-1 reduced prostate-specific antigen (PSA) levels in a dose-related manner. PSA is an FDA-recognized biomarker where higher levels generally indicate more active tumor behavior.

The company also highlighted prior mouse data in a PC3 xenograft model of aggressive, non-androgen-related prostate cancer, where Telomir-1 reduced tumor volume as a single agent, and in combination with paclitaxel achieved full tumor volume reduction without treatment-related mortality, while paclitaxel alone caused high mortality. Telomir continues preclinical development of Telomir-1 across oncology, aging biology, autism-related pathways and other age-associated conditions, and is advancing IND-enabling work toward a planned IND submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
current report
-
Rhea-AI Summary

Telomir Pharmaceuticals, Inc. reported that Board member Craig Eagle resigned from the Board of Directors, effective November 14, 2025. The company states that his resignation was not due to any disagreement with Telomir, its management, or any other Board member. The Board expressed appreciation for his service. A copy of Mr. Eagle’s resignation letter is included as Exhibit 17.1 to this report.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
current report
Rhea-AI Summary

Telomir Pharmaceuticals (TELO) is asking stockholders to approve a merger with private TELI Pharmaceuticals at a virtual annual meeting on December 30, 2025. The key item is authorization to issue TELO common stock and other securities in the merger equal to more than 20% of TELO shares outstanding, along with electing four directors, ratifying the auditor, amending the 2023 Omnibus Incentive Plan and bylaws, approving director option grants, and allowing adjournments.

Under the Merger Agreement, TELI stockholders will exchange their TELI shares for TELO common stock based on an exchange ratio derived from valuations of about $101.1 million for TELO and $126.8 million for TELI. Immediately after closing, pre‑merger TELO and TELI holders are expected each to own approximately 50% of TELO on a non‑diluted basis, shifting to about 59% for TELI holders on a fully diluted basis when 14,250,000 Telomir‑linked warrants at $2.00 per share are included.

TELO holds U.S. rights to the pre‑clinical drug candidate Telomir‑1, while TELI licenses major international rights, so the merger is intended to consolidate global Telomir‑1 development and commercialization within a single Nasdaq‑listed company. The board unanimously recommends voting in favor of all proposals but highlights extensive risk factors, including TELI’s lack of revenue, significant funding needs for combined operations, clinical and regulatory uncertainty, competitive pressures, and potential dilution to existing TELO stockholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
proxy
-
Rhea-AI Summary

Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) reported new preclinical results showing its investigational small molecule Telomir-1 killed aggressive human leukemia (HL60) cells in vitro. The compound produced a clear, dose-dependent reduction in leukemia cell viability in this widely used model of acute myeloid leukemia.

The company links these findings to earlier research where Telomir-1 markedly reduced intracellular Fe²⁺ levels in human cell systems, with stronger cell-penetrating, iron-lowering activity than the chelator Deferoxamine at the same concentrations. Telomir-1 has also been shown to reduce abnormal DNA methylation in tumor-suppressor genes such as STAT1, CDKN2A, MASPIN, RASSF1A, CASP8, and GSTP1, and to inhibit key lysine histone demethylase (KDM2, KDM5, KDM6) enzyme families. Together, these iron-modulating and epigenetic effects support Telomir’s broader oncology research program, which already includes models of triple-negative breast, pancreatic, and aggressive prostate cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
current report
-
Rhea-AI Summary

Telomir Pharmaceuticals filed an 8-K reporting new preclinical results for Telomir-1. In human keratinocyte (HaCaT) cells, Telomir-1 produced a strong, dose- and time-dependent reduction of intracellular ferrous iron (Fe²⁺), with greater effect than the FDA‑approved iron chelator Deferoxamine (DFO) under equivalent conditions.

The study used FerroOrange live-cell imaging and observed lower Fe²⁺ signal at three, six, and sixteen hours, indicating cell penetration and iron‑modulating activity at low concentrations. The company also noted a zinc‑formulated version, Telomir‑Zn, designed to exchange metal ions by binding excess reactive metals such as iron and copper while contributing zinc, a cofactor for enzymes tied to antioxidant defense and DNA stability. The findings support ongoing research into metal‑ion balance, oxidative stress, and epigenetic regulation in aging and degenerative disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
current report
Rhea-AI Summary

Telomir Pharmaceuticals (NASDAQ: TELO) filed its Q3 2025 10‑Q, reporting ongoing preclinical development and continued losses. Net loss was $1.1 million for the quarter and $8.4 million year‑to‑date, with no revenue. Operating costs in Q3 were $1.15 million, driven by $0.76 million in R&D and $0.39 million in G&A.

Cash rose to $7.33 million as of September 30, 2025, supported by financings: $5.55 million in ATM proceeds during the nine months and a $3.0 million related‑party equity investment at a premium. Subsequent to quarter end, the company raised an additional $1.00 million via ATM block sales. The company disclosed substantial doubt about its ability to continue as a going concern despite indicating current cash is expected to fund operations through the third quarter of 2026.

Shares outstanding were 33,830,971 at September 30, 2025 and 34,380,971 as of November 7, 2025. Telomir executed a binding LOI on October 17, 2025 to acquire TELI Pharmaceuticals, aiming to consolidate worldwide rights to Telomir‑1, with up to $5 million in potential shareholder contributions tied to milestones, subject to approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.65%
Tags
quarterly report
-
Rhea-AI Summary

Telomir Pharmaceuticals (TELO) announced new preclinical data on Telomir-1 in a mouse model of aggressive prostate cancer, focusing on DNA methylation changes in two defense genes, CASP8 (apoptosis) and GSTP1 (glutathione-based detoxification).

On Day 21, Telomir-1 was associated with reduced DNA methylation of both CASP8 and GSTP1 versus vehicle and chemotherapy, suggesting potential re-activation of apoptosis and detoxification-related gene functions. The combination of Telomir-1 and chemotherapy showed lower methylation than chemotherapy alone in this model. Rapamycin showed an initial reduction at Day 10 that partially rebounded by Day 21, while Telomir-1 continued a progressive, more sustained decrease. The company believes DNA-methylation control may be an important area of ongoing evaluation for Telomir-1 in oncology research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
current report
-
Rhea-AI Summary

Telomir Pharmaceuticals (NASDAQ: TELO) signed a binding LOI to acquire TELI Pharmaceuticals in a stock-for-stock deal, consolidating worldwide intellectual property and development rights to its lead candidate, Telomir-1.

The agreement includes up to $5 million in cash contributions from certain TELI shareholders: $1 million at closing, $2 million upon FDA acceptance of an IND, and $2 million upon initiation of a Phase 1/2 study. Shares tied to the $4 million in milestone contributions will be allocated at closing and issued upon receipt of each payment. Closing is not contingent on receiving the milestone funds.

The LOI imposes a six-month lockup on shares issued to TELI holders and is subject to due diligence, board and stockholder approvals, regulatory clearances, and definitive agreements. If completed, Telomir would hold unified global rights to Telomir-1, aiming to simplify development and partnering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
current report
Rhea-AI Summary

Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical findings showing that its small molecule Telomir-1 reduced survival of aggressive human pancreatic cancer (PANC-1) cells in vitro. The compound produced a concentration-dependent decrease in cell viability and mitochondrial activity, aligning with prior results in triple‑negative breast and prostate cancer models.

The response in pancreatic cells was partially reversed by iron re‑addition, indicating iron‑dependent processes contribute to the effect, while incomplete rescue suggests additional metabolic or epigenetic mechanisms. Telomir-1 has been associated with tumor suppressor genes and iron‑dependent histone demethylases relevant to pancreatic cancer, including MASPIN (SERPINB5), RASSF1A, STAT1, KDM2B, and KDM6B. The company noted pancreatic cancer’s five‑year survival rate is about 12 percent. Telomir plans to expand preclinical research to additional models, including leukemia, and to initiate in vivo validation studies as part of ongoing IND preparation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.50%
Tags
current report

FAQ

How many Telomir Pharmaceuticals (TELO) SEC filings are available on StockTitan?

StockTitan tracks 60 SEC filings for Telomir Pharmaceuticals (TELO), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Telomir Pharmaceuticals (TELO)?

The most recent SEC filing for Telomir Pharmaceuticals (TELO) was filed on November 18, 2026.